- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05737433
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Rencofilstat in Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, open-label, non-randomized, single period, single dose study in healthy male subjects designed to assess the mass balance recovery, pharmacokinetics (PK), metabolite profile and metabolite identification of rencofilstat. It is planned to enroll a single cohort of 6 subjects. All subjects will receive a single 225 mg oral dose of [14C]-rencofilstat, as a SMEDDS oral emulsion in the fasted state.
Subjects will undergo preliminary screening procedures for the study at the screening visit (Day -28 to Day -2). Subjects will be admitted in the evening on the day before dosing (Day-1).
Whole blood, plasma, urine and feces samples will be collected at regular intervals for PK analysis, total radioactivity analysis, metabolite profiling, mass balance and safety as applicable, from pre-dose to discharge from the clinical unit. Urine and feces samples may be collected at return visits or home visits if mass balance criteria have not been met by a subject.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Jill Greytok
- Phone Number: 732-902-4016
- Email: jgreytok@hepionpharma.com
Study Locations
-
-
-
Nottingham, United Kingdom
- Quotient Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening
- Must be willing and able to communicate and participate in the whole study
- Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)
- Must provide written informed consent
- Must agree to adhere to the contraception requirements
Exclusion Criteria:
- Subjects who have received any investigational treatment in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
- Subjects who are, or are immediate family members of, a study site or sponsor employee
- Evidence or history of current SARS-CoV-2 infection within 4 weeks prior to study drug administration
- History of any drug or alcohol abuse in the past 2 years prior to screening
- Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
- A confirmed positive alcohol breath test at screening or admission
- Current smokers and those who have smoked within the last 12 months prior to screening
- A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
- Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months prior to screening
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
- Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator or delegate at screening
- Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects known to have Gilbert's syndrome are excluded
- Confirmed positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results
- Evidence of renal impairment at screening, as indicated by an estimated eGFR of <60 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration equation
- History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, malabsorptive, neurological or psychiatric disorder, as judged by the investigator
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
- Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
- Subjects who have taken known strong or moderate CYP3A4 inducers in the 30 days before IMP administration
- Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) in the 14 days before study drug administration. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no pharmacodynamic activity is expected by the time of dosing with study drug; and if the use of medication does not jeopardize the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study
- Subjects who have had a COVID-19 vaccine 7 days before dosing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]-RCF 225mg
[14C]-rencofilstat, 225mg oral dose, self-micro-emulsifying drug delivery system, single dose
|
radio-labelled 225mg oral dose of rencofilstat
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the mass balance recovery after a single oral dose of [14C]-rencofilstat
Time Frame: 22 Days
|
Cumulative amount of total radioactivity recovered.
|
22 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Litza McKenzie, MD, Quotient Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEPA-CRV431-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NASH With Fibrosis
-
Hepion Pharmaceuticals, Inc.Active, not recruitingNASH With FibrosisUnited States
-
Akero Therapeutics, IncRecruitingNASH With Fibrosis | MASH With FibrosisUnited States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain
-
Active Genomes Expressed Diagnostics, CorpWalter Reed National Military Medical Center; Arizona Clinical TrialsNot yet recruitingHealthy | NAFLD | NASH With FibrosisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingNAFLD | Liver Fibrosis | NASH With FibrosisNetherlands
-
AstraZenecaRecruiting
-
GenfitTerminatedNonalcoholic Steatohepatitis (NASH) With FibrosisUnited States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
-
Enanta Pharmaceuticals, IncPRA Health SciencesCompletedNASH - Nonalcoholic Steatohepatitis With Liver FibrosisNetherlands
-
TaiwanJ Pharmaceuticals Co., LtdNot yet recruitingNonalcoholic Steatohepatitis (NASH) With Fibrosis
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Julius ClinicalUMC Utrecht; Erasmus Medical Center; Sint Franciscus GasthuisNot yet recruitingObesity | Metabolic Syndrome | Type 2 Diabetes | NAFLD | Fibrosis, Liver | Arterial Hypertension | NASH | NASH With Fibrosis | Steatosis of Liver
Clinical Trials on [14C]-rencofilstat 225mg
-
Hepion Pharmaceuticals, Inc.Active, not recruitingNASH With FibrosisUnited States
-
Hepion Pharmaceuticals, Inc.RecruitingNAFLD | Nonalcoholic Steatohepatitis (NASH) | Fibrosis, LiverUnited States, France, Mexico
-
Chicago Headache Center & Research InstituteRecruitingChronic Migraine, HeadacheUnited States
-
Hepion Pharmaceuticals, Inc.CompletedFibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver DiseaseUnited States, Puerto Rico
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
BiogenDenali Therapeutics Inc.Completed
-
Denovo Biopharma LLCCompleted
-
Athira PharmaAlturas Analytics, Inc.; Labcorp Drug Development IncCompletedHealthy VolunteersUnited States
-
Laekna LimitedCompleted